Oncology Business Management | Specialty

The Ongoing Debate Over Mammography-Screening Matters

October 1st 2014

Prophylactic Double Mastectomy-Does it Make a Difference?

October 1st 2014

ATEMPT Trial at Dana-Farber Cancer Institute

October 1st 2014

BRCA Screening Recommendations by Geneticist Mary-Claire King

October 1st 2014

Latest News & Insight: October 1, 2014

October 1st 2014

Physician Providers Still Lagging in ICD-10 Readiness

September 26th 2014

Although the ICD-10 launch was moved to October 1, 2015, vendors and health plans look to be making some progress on the switchover. The same can't be said for physician providers, however.

Practices in Bundled Payment Program Credit Medical Home Structure for Success

September 26th 2014

In July, UnitedHealthcare (UHC) reported that an innovative program using bundled payment for cancer care resulted in an impressive 34% reduction in medical costs when compared with costs for a control group

Amgen Seeks FDA Approval for Blinatumomab in ALL

September 22nd 2014

A Biologics License Application has been submitted to the FDA for the bispecific T-cell engager (BiTE) antibody blinatumomab as a treatment for adult patients with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

Dr. Lazarus Discusses Companion Diagnostics

September 18th 2014

Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.

When Science Outpaces Payers: Molecular Diagnostics Pose Reimbursement Dilemmas

September 17th 2014

As precision medicine continues to evolve in cancer care, the development of highly sophisticated tests that leverage the explosion of knowledge about the molecular and protein characteristics of an individual patient's tumor has emerged as its own scientific frontier.

Blood-Based Biomarkers Predict Outcomes Following Neoadjuvant Treatment in Esophageal Cancer

September 16th 2014

High pretreatment levels of serum VEGF-A and TGF-β1 indicated significantly worse disease-free survival (DFS) following neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Differences Identified Between What Medicare Covers and What Patients with Cancer Want

September 15th 2014

Does Medicare coverage for patients with cancer match up to what they actually want covered? There appears to be a mismatch between covered benefits and beneficiary preferences that involves quality of life and financial burden of care, according to a study from Duke University.

Urologists Discuss Their Use of Biomarker Tests in Considering Active Surveillance

September 12th 2014

Experts Touch On Oncotype DX, Other Assays During Peer Exchange

Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer

September 11th 2014

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.

FDA Approves Pre-Chemo Enzalutamide for mCRPC

September 10th 2014

The FDA has expanded the approval for enzalutamide to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

Dr. Yang Discusses the Future of Lung Cancer Treatment

September 10th 2014

James CH Yang, MD, PhD, from the National Taiwan University Hospital, discusses the future of lung cancer treatment.

Two Webinars Address Oncology Bundled Payments

September 8th 2014

Don't look now but a consensus that bundled payments is the best payment reform strategy is emerging, and it's expected that many pilot and demonstration projects will start soon.

Life After Obamacare

September 8th 2014

If one had to choose a single word to describe the future of Obamacare, it would probably be "uncertain."

Bristol-Myers Squibb Challenges Patent on Merck's Pembrolizumab

September 5th 2014

BMS has filed a lawsuit over Merck's newly approved immunotherapy drug pembrolizumab, contending that the much-heralded PD-1 inhibitor will infringe upon patents that Bristol-Myers holds on the groundbreaking technology.

Where Should Cancer Care Be Delivered and Why?

August 28th 2014

There is a growing chorus that seems to be debating separate issues-340B drug pricing, the sequester, site of service differential, etc. But the debate revolves around a singular issue-where should cancer care be delivered?